UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000010895 |
|---|---|
| Receipt number | R000012749 |
| Scientific Title | The study for the efficacy of amlodipine/atorvastatin combination drug in patients with type 2 diabetes complicated with hypertention and hypercholestrolemia. |
| Date of disclosure of the study information | 2013/06/08 |
| Last modified on | 2016/03/08 09:52:20 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The study for the efficacy of amlodipine/atorvastatin combination drug in patients with type 2 diabetes complicated with hypertention and hypercholestrolemia.
Acronym
Caduet clinical research
Scientific Title
The study for the efficacy of amlodipine/atorvastatin combination drug in patients with type 2 diabetes complicated with hypertention and hypercholestrolemia.
Scientific Title:Acronym
Caduet clinical research
Region
| Japan |
Condition
Condition
Type 2 diabetes complicated with hypertention and hypercholestrolemia
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
The aim of this study is to investigatethe efficasy of amlodipine/atorvastatin combination drug in patients eith type 2 diabetes complicated with hypertentions and hypercholesterolemia,and which patients receive the treatment for hypertension with amolodipine besilate and do not achieve the lipid management goals,regardless with or without medication for hypercholesterolemia.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
1)The amount of change in serum LDL-C levels between at baseline and after 6 months.
2)The amount of change in systolic blood pressure between at baseline and after 6 months.
Key secondary outcomes
1)The amount of change in serum LDL-C levels between at baseline and after 12 months.
2)The amount of change in systolic blood pressure between at baseline and after 12 months.
3)Achievement rate of lipid management goal of after 6 and 12 months.
4)The amount of change in the follwing items between at the baseline and 6 months or 12 months.
Diastolic blood pressure.
8-iso-PGF2 concentration in blood
The amount of change in oxidized LDL
Fasting blood glucose level
The amount of change in HbA1c
Cystatin-C concentration
Urinary albumin / creatinine ratio
eGFR
Blood adiponectin concentration
5)The amount of change in carotid IMT between at baseline and 6 or 12 months.
6)Adverse events.
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -but assessor(s) are blinded
Control
Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Switching to amlodipine / atorvastatin combination drug.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Outpatient
2) Patients receiving the treatment with amlodipine besilate for more than 3 months,at the time of registration.
3) Patients whose serum LDL-C levels are more than 120mg/dl,regardless with or without medication for hypercholesterolemia,at the time of registration.
4) Patients who can obtain voluntary conset documents for participation in this study,after a sufficient informed consent.
Key exclusion criteria
1) Patients whose systolic blood pressure is more than 180mmHg and diastolic blood pressure is more than 110mmHg and whose blood pressure are not well-controlled and considered to add or increase the dose of hypertensive drugs druing this study.
2) Secondry hypertention patiebs.
3) Familial hypercholesterolemia patients.
4) Patients with secondary prevention who developed cardiovascular events,such as acute myocardial infarction and cerebral infarction in the past.
5) Patients with severe heart failure patients.
6) Patients with severe arrhythmias.
7) eGFR is less than 40ml/min/1.73 square meters.
8) Patients with advanced liver failure.
9) Patients with active malignancy.
10)Patients during administration of immunosuppressants or steroid.
11) Women who are pregnant or possibly pregnant or wish to pregnant or lactating.
12)Patients with allergy or contraindication to test drug.
13) Intellectually or mentally disabled patients who are impossible to agree or with suspected ability to agree.
14) Patients judged not suitable by the attending physician.
Target sample size
240
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Daisuke Koya |
Organization
Kanazawa Medical University
Division name
Diabetes and Endocrinology
Zip code
Address
Daigaku1-1 Uchinadamachi Kahokugun Ishikawaken
TEL
076-286-2211
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Munehiro Kitada |
Organization
Kanazawa Medical University
Division name
Diabetes and Endocrinology
Zip code
Address
Daigaku1-1 Uchinadamachi Kahokugun Ishikawaken
TEL
076-286-2211
Homepage URL
Sponsor or person
Institute
Kanazawa Medical University
Diabetes and Endocrinology
Institute
Department
Personal name
Funding Source
Organization
Kanazawa Medical University
Diabetes and Endocrinology
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2013 | Year | 06 | Month | 08 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2013 | Year | 03 | Month | 11 | Day |
Date of IRB
Anticipated trial start date
| 2013 | Year | 06 | Month | 08 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2013 | Year | 06 | Month | 07 | Day |
Last modified on
| 2016 | Year | 03 | Month | 08 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012749
